Adedamola Bayo-Olugbami1, Abdulrazaq Bidemi Nafiu2, Abdulbasit Amin3, Olalekan Michael Ogundele4, Charles C Lee4, Bamidele Victor Owoyele3. 1. Department of Physiology, Adeleke University, Ede, Nigeria. 2. Department of Human Physiology, Federal University Dutse, Dutse, Nigeria. 3. Neuroscience & Inflammation unit, Department of Physiology, University of Ilorin, Ilorin, Nigeria. 4. Department of Comparative Biomedical Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA, USA.
Abstract
Background: L-DOPA, the predominant therapy for Parkinson's disease (PD) is associated with motor deficits after prolonged use. The nigrostriatal tract, a primary target of neurodegeneration in PD, contains abundant Vitamin-D receptors, suggesting a potential role for VD in the disease. Therefore, we tested the impact of Vitamin D3 (VD3) in a mouse model of PD. Methods: PD was induced in adult male C57BL6 mice by a single intrastriatal injection of 6-hydroxydopamine. Two weeks post lesion, these mice received injections of a vehicle, VD3, L-DOPA, or a combination of VD3/L-DOPA and compared with sham controls. Treatment lasted three weeks, during which motor-cognitive neurobehaviour was assessed. Five weeks post lesion, brains were collected and striatal levels of the following proteins assessed: tyrosine hydroxylase (TH), dopamine decarboxylase (DDC), monoamine oxidase (MAO-B), Catechol-O-methyl transferase (COMT), dopamine transporter (DAT), brain-derived neurotrophic factor (BDNF), microglia marker (CD11b), inflammation (IL-1β), apoptotic signaling (BAX) and oxidative stress (p47phox). Results: Treatment with VD3 attenuated behavioural deficits induced by 6-OHDA, protein associated with dopamine metabolism and biomarkers of oxidative stress. VD3 significantly increased contralateral wall touches, exploratory motor and cognitive activities. VD3 significantly enhanced the expression of TH, DAT, BDNF, while significantly reducing expression of MAO-B, CD11b, IL-I β and p47phox. Conclusion: VD3 reversed some of the 6-OHDA induced changes in proteins involved in modulating the dopamine system, behavioural deficits and oxidative stress biomarkers. The data suggests that VD3 might be beneficial in reducing L-DOPA dosage, thereby reducing problems associated with dosage and prolonged use of L-DOPA in PD management.
Background: L-DOPA, the predominant therapy for Parkinson's disease (PD) is associated with motor deficits after prolonged use. The nigrostriatal tract, a primary target of neurodegeneration in PD, contains abundant Vitamin-D receptors, suggesting a potential role for VD in the disease. Therefore, we tested the impact of Vitamin D3 (VD3) in a mouse model of PD. Methods: PD was induced in adult male C57BL6 mice by a single intrastriatal injection of 6-hydroxydopamine. Two weeks post lesion, these mice received injections of a vehicle, VD3, L-DOPA, or a combination of VD3/L-DOPA and compared with sham controls. Treatment lasted three weeks, during which motor-cognitive neurobehaviour was assessed. Five weeks post lesion, brains were collected and striatal levels of the following proteins assessed: tyrosine hydroxylase (TH), dopamine decarboxylase (DDC), monoamine oxidase (MAO-B), Catechol-O-methyl transferase (COMT), dopamine transporter (DAT), brain-derived neurotrophic factor (BDNF), microglia marker (CD11b), inflammation (IL-1β), apoptotic signaling (BAX) and oxidative stress (p47phox). Results: Treatment with VD3 attenuated behavioural deficits induced by 6-OHDA, protein associated with dopamine metabolism and biomarkers of oxidative stress. VD3 significantly increased contralateral wall touches, exploratory motor and cognitive activities. VD3 significantly enhanced the expression of TH, DAT, BDNF, while significantly reducing expression of MAO-B, CD11b, IL-I β and p47phox. Conclusion: VD3 reversed some of the 6-OHDA induced changes in proteins involved in modulating the dopamine system, behavioural deficits and oxidative stress biomarkers. The data suggests that VD3 might be beneficial in reducing L-DOPA dosage, thereby reducing problems associated with dosage and prolonged use of L-DOPA in PD management.
Authors: C Annweiler; E Dursun; F Féron; D Gezen-Ak; A V Kalueff; T Littlejohns; D J Llewellyn; P Millet; T Scott; K L Tucker; S Yilmazer; O Beauchet Journal: J Intern Med Date: 2014-07-19 Impact factor: 8.989
Authors: Roberta Oliveira da Costa; Carlos Vinicius Jataí Gadelha-Filho; Pedro Everson Alexandre de Aquino; Ludmila Araújo Rodrigues Lima; Jalles Dantas de Lucena; Wesley Lyeverton Correia Ribeiro; Francisco Arnaldo Viana Lima; Kelly Rose Tavares Neves; Glauce Socorro de Barros Viana Journal: Neurochem Res Date: 2022-08-26 Impact factor: 4.414
Authors: Alshimaa Magdy; Eman A E Farrag; Shereen Mohamed Hamed; Zienab Abdallah; Eman Mohamad El Nashar; Mansour Abdullah Alghamdi; Amira A H Ali; Marwa Abd El-Kader Journal: Front Cell Neurosci Date: 2022-09-16 Impact factor: 6.147